✦Corporate brand & media services✦Made in Virginia Beach since 1997✦Boards engagement today people · AI✦
Old boatGrew revenue 17.8% in FY2025 to $37 million, operating margin -65.4% against a 1.2% median for surgical & medical instruments & apparatus, equity 28.7% of assets.
Last filing8-K · Item 1.01 Entry into a Material Definitive Agreement, 18 Nov 2026
🫧 Edgar looked up ClearPoint Neuro, Inc. ($CLPT). Last filing: 8-K (1.01 Entry into a Material Definitive Agreement), 2026-11-18. 9 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $37.0M (FY2025), total debt $49.1M. Experience: revenue up 17.8% on the year, up 22.7% a year over 4 years; operating margin -65.4%, down from -62.9%. Soundness: equity 28.7% of assets, return on equity -91.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $29.9M and $62.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $28.5M to $65.9M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -65.4% against a 1.2% median; growth 17.8% against 11.6%.
Read from its own SEC filings · nothing written, nothing inferred
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$24M · $1M · $50M · −$24M |
| Investment book (cash · short · long) | $46M · — · — · current ratio 5.91 |
| Revenue swing · equity of assets | 5.5% · 28.7% |
ClearPoint Neuro is growing faster than its size class, with steadier revenue. Its own audited SEC figures.
| Fiscal year end | 2025-12-31 |
| Revenue | $37M |
| Revenue, on the year | 17.8% |
| Revenue, a year over the record | 22.7% |
| Operating margin | −65.4% |
| Operating margin, prior year | −62.9% |
| Net margin | −69.1% |
| Research and development | $14M · 37.6% of revenue |
| Total debt | $49M |
| Equity of assets | 28.7% |
| Return on equity | −91.1% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.9 |
| Book value per share | $0.99 |
| Revenue per share | $1.31 |
| Shares outstanding | 28,315,254 |
| Audited years read | 5 |
Peers: the median of 60 filers with $50M+ revenue in surgical & medical instruments & apparatus.
Classic signals · fiscal 2025Altman Z″ -4.93 distress zone 1968Piotroski F 4 of 9 middling 2000Beneish M -1.76 above the −1.78 line 1999Sloan accruals -2.4% earnings backed by cash 1996DuPont ROE -95.6% = margin -69.1% × turns 0.54 × leverage 2.56
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health watch · 12 monthsDirector or officer change
Versus peersoperating margin −65.4% vs a 1.2% median · revenue growth 17.8% vs 11.6% · cash beats 38% of its size class · growth beats 72% 60 surgical & medical instruments & apparatus filers
Trend · last year to this▼operating margin −62.9% → −65.4% · ▲revenue $31.4M → $37.0M · 5-year revenue: $16.3M · $20.6M · $24.0M · $31.4M · $37.0M
| # | Company | Condition | Operating margin | Revenue growth | Sales | |
|---|---|---|---|---|---|---|
| 1 | ![]() | Lemaitre VascularLMAT | New ship | 27.2% | 13.5% | $249.6M |
| 2 | ![]() | DexcomDXCM | New ship | 19.6% | 15.6% | $4.7B |
| 3 | ![]() | StrykerSYK | New ship | 19.5% | 11.2% | $25.1B |
| 4 | ![]() | MedlineMDLN | New ship | 7.8% | 11.5% | $28.4B |
| 5 | ![]() | ResMedRMD | Sound ship | 33.4% | 9.9% | $5.7B |
| 6 | ![]() | West Pharmaceutical ServicesWST | Sound ship | 19.0% | 6.3% | $3.1B |
| 7 | ![]() | 3M CompanyMMM | Sound ship | 18.6% | 1.5% | $24.9B |
| 8 | ![]() | Boston ScientificBSX | Sound ship | 18.0% | 19.9% | $20.1B |
| 9 | ![]() | InsuletPODD | Sound ship | 17.5% | 30.7% | $2.7B |
| 10 | ![]() | Interpace BiosciencesIDXG | Sound ship | 10.5% | −17.5% | $38.7M |
| 11 | ![]() | Infusystem HoldingsINFU | Sound ship | 8.3% | 6.4% | $143.4M |
| 12 | ![]() | NephrosNEPH | Sound ship | 6.1% | 32.7% | $18.8M |
| 13 | ![]() | AngioDynamicsANGO | Sound ship | −12.5% | 9.5% | $320.2M |
| 14 | ![]() | Bluejay DiagnosticsBJDX | Sound ship | −3741.5% | — | $0.2M |
| 15 | ![]() | Modular MedicalMODD | Sound ship | — | — | $0.0M |
| 16 | ![]() | Microbot MedicalMBOT | Weathered boat | 782.8% | −88.5% | $0.1M |
| 17 | ![]() | Pro-DexPDEX | Weathered boat | 16.8% | 16.5% | $77.5M |
| 18 | ![]() | Sanuwave HealthSNWV | Weathered boat | 11.2% | 35.0% | $44.1M |
| 19 | ![]() | MiniMed GroupMMED | Weathered boat | −6.1% | 14.3% | $3.1B |
| 20 | ![]() | iRhythm HoldingsIRTC | Weathered boat | −7.7% | 26.2% | $747.1M |
| 21 | ![]() | SI-Bone, Inc.SIBN | Weathered boat | −11.1% | 20.2% | $200.9M |
| 22 | ![]() | NovoCure LimitedNVCR | Weathered boat | −23.5% | 8.3% | $655.4M |
| 23 | ![]() | Integra Lifesciences HoldingsIART | Weathered boat | −30.2% | 1.5% | $1.6B |
| 24 | ![]() | Procept BioRoboticsPRCT | Weathered boat | −33.7% | 37.2% | $308.1M |
| 25 | ![]() | Beta BionicsBBNX | Weathered boat | −71.5% | 53.9% | $100.3M |
| 26 | ![]() | enVVeno MedicalNVNO | Weathered boat | −24566.5% | −83.3% | $0.0M |
| 27 | ![]() | Autonomix MedicalAMIX | Weathered boat | — | — | $0.0M |
| 28 | ![]() | Odyssey HealthODYY | Weathered boat | — | — | $0.0M |
| 29 | ![]() | GlucotrackGCTK | Old boat | 1685.6% | 378.3% | $0.2M |
| 30 | ![]() | Teleflex IncorporatedTFX | Old boat | 5.9% | 17.2% | $2.0B |
| 31 | ![]() | Accuray IncorporatedARAY | Old boat | −6.6% | −12.3% | $401.9M |
| 32 | ![]() | SkinHealth SystemsSKIN | Old boat | −6.9% | −10.0% | $300.8M |
| 33 | ![]() | Sonoma PharmaceuticalsSNOA | Old boat | −12.6% | 36.7% | $19.5M |
| 34 | ![]() | CarlsmedCARL | Old boat | −60.5% | 85.9% | $50.5M |
| 35 | ![]() | CVRxCVRX | Old boat | −90.5% | 10.4% | $56.7M |
| 36 | ![]() | Orchestra BioMed HoldingsOBIO | Old boat | −154.7% | 1169.2% | $33.5M |
| 37 | ![]() | Profound MedicalPROF | Old boat | −256.3% | 50.7% | $16.1M |
| 38 | ![]() | Intelligent Bio SolutionsINBS | Old boat | −299.1% | 38.1% | $4.2M |
| 39 | ![]() | Tenon MedicalTNON | Old boat | −324.3% | 20.4% | $3.9M |
| 40 | ![]() | Beyond AirXAIR | Old boat | −378.2% | 107.3% | $7.7M |
| 41 | ![]() | InspireMDNSPR | Old boat | −552.6% | 28.1% | $9.0M |
| 42 | ![]() | FemasysFEMY | Old boat | −767.0% | 40.8% | $2.3M |
| 43 | ![]() | Harvard Apparatus Regenerative TechnologyHRGN | Old boat | −982.2% | 63.7% | $0.7M |
| 44 | ![]() | SeaStar Medical HoldingICU | Old boat | −986.6% | 814.1% | $1.2M |
| 45 | ![]() | Lucid DiagnosticsLUCD | Old boat | −1054.8% | 8.3% | $4.7M |
| 46 | ![]() | ProfusaPFSA | Old boat | −4500.0% | — | $0.1M |
| 47 | ![]() | VivosRDGL | Old boat | −4628.7% | 144.3% | $0.1M |
| 48 | ![]() | CO-DiagnosticsCODX | Old boat | −8058.8% | −84.1% | $0.6M |
| 49 | ![]() | Pulse BiosciencesPLSE | Old boat | −21982.6% | — | $0.3M |
| 50 | ![]() | PAVmedPAVM | Old boat | −30712.7% | −97.6% | $0.1M |
| 51 | ![]() | StimCell EnergeticsSTME | Old boat | — | −100.0% | $0.0M |
| 52 | ![]() | Fractyl HealthGUTS | Old boat | — | −100.0% | $0.0M |
| 53 | ![]() | Global Innovative PlatformsGIPL | Old boat | — | — | $0.0M |
| 54 | ![]() | Adagio Medical Holdings, Inc.ADGM | Old boat | — | −100.0% | $0.0M |
| 55 | ![]() | BiotricityBTCY | Rotting at the dock | 10.6% | 16.0% | $16.0M |
| 56 | ![]() | Premier Air Charter HoldingsPREM | Rotting at the dock | −8.5% | 53.6% | $31.9M |
| 57 | ![]() | SS Innovations InternationalSSII | Rotting at the dock | −19.3% | 105.7% | $42.5M |
| 58 | ![]() | NeuroneticsSTIM | Rotting at the dock | −21.1% | 99.2% | $149.2M |
| 59 | ![]() | NexGelNXGL | Rotting at the dock | −29.3% | 31.5% | $11.4M |
| 60 | ![]() | CytosorbentsCTSO | Rotting at the dock | −39.8% | 4.1% | $37.1M |
| 61 | ![]() | Tela BioTELA | Rotting at the dock | −42.0% | 15.8% | $80.3M |
| 62 | ![]() | Spectral AIMDAI | Rotting at the dock | −43.8% | −33.6% | $19.6M |
| 63 | ![]() | Nuo TherapeuticsAURX | Rotting at the dock | −76.0% | 142.7% | $3.3M |
| 64 | ![]() | Invo FertilityIVF | Rotting at the dock | −105.8% | 4.3% | $6.8M |
| 65 | ![]() | Vivos TherapeuticsVVOS | Rotting at the dock | −114.1% | 16.0% | $17.4M |
| 66 | ![]() | DarioHealthDRIO | Rotting at the dock | −163.9% | −17.3% | $22.4M |
| 67 | ![]() | Picard MedicalPMI | Rotting at the dock | −268.4% | 12.5% | $4.9M |
| 68 | ![]() | Osr HealthOSRH | Rotting at the dock | −631.0% | −17.7% | $2.9M |
| 69 | ![]() | PetVivo HoldingsPETV | Rotting at the dock | −793.9% | 0.8% | $1.1M |
| 70 | ![]() | Sintx TechnologiesSINT | Rotting at the dock | −1053.1% | −64.7% | $1.0M |
| 71 | ![]() | Flyte AviationVJET | Rotting at the dock | −2581.6% | 95.0% | $0.8M |
From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.
Sailing speed follows growth: 21.6% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Brand success factors · calendar 2025
Exponential Success Score
Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.
How The Trillion Score works. We read eight measures of success from ClearPoint Neuro's own SEC filings and test each one against the public companies in its field, here surgical & medical instruments & apparatus. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.
What it says here. At 548, ClearPoint Neuro's odds of thriving come to 44%, against about 37% for the typical filer. It meets 4 of 8 success points.
The higher the score, the more often companies went on to thrive. At this level, about 38 of every 100 did.
Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.
Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 41 of every 100 companies in the High band did. That is the group's history, not a forecast for this company.
| Money | It burned about 66 cents of free cash on each sales dollar after paying for its plants and equipment. Its cash would cover that burn for about 1.9 years. Debt after cash comes to about 9 cents for each dollar of yearly sales. | cash negative over five years |
| Swings | Even in its worst years on record, sales still grew. | 13.4% a year |
| Filed events | In the last two years it told the SEC about 2 filings on leadership or auditor changes. | 2 |
| Point | What it means | Place in field | |
|---|---|---|---|
| Speed | Sales grew faster than most of its field. | 78 of 100 | Met |
| Steadiness | Growth was strong for how much it swung, so it looks dependable. | 98 of 100 | Met |
| Price premium | It keeps less of each sales dollar than the leaders in its field. | 52 of 100 | Not yet |
| Margin stays above the field | Its margin has held above the field year after year. | 60 of 100 | Met |
| Moat half-life | Its margin edge is fading fast, or it has none yet. | 53 of 100 | Not yet |
| Brand spend yield | Brand spending returns less gross profit than for the leaders in its field. | 59 of 100 | Not yet |
| Learning curve | Costs have not fallen much as a share of sales as it grew. | 21 of 100 | Not yet |
| Climb in the field | It has been moving up the size ranks in its field. | 79 of 100 | Met |
Price premium $0M is the extra gross profit over a field-median margin. Momentum $2M is gross profit times growth above the field's pace.
| Credibility | With 8 years of filings, the record earns 70% of the weight. The rest stays at the middle of the field. | 0.70 |
| Severe decline, class B | About 26 of every 100 companies with this many points fell 30% or stopped reporting within three years. | 26.1% |
| Actual vs expected | Sales are 37% higher than if it had simply kept pace with its field. | 1.37 |
Top of its field: #1 SANUWAVE Health · #2 AVITA Medical · #3 TELA Bio · #4 Inspire Medical Systems · #5 Insulet
Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·
Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time info@pops4.comNine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.